The development of antibody delivery systems to target cancer with highly potent maytansinoids

Expert Opinion on Investigational Drugs

Volumn 6, Issue 2, 1997, Pages 169-172

  Liu, C ^a   Chari, R V J ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

antibody; cancer therapy; immunoconjugates; maytansinoids

Indexed keywords

ANTIBODY CONJUGATE; C242 DM1; CYTOTOXIC AGENT; FLUOROURACIL; MAYTANSINE DERIVATIVE; MAYTANSINOID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C242; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CANCER CELL CULTURE; CANCER GRAFT; CANCER THERAPY; COLON CANCER; COMBINED IMMUNODEFICIENCY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; HUMAN; MOUSE; NONHUMAN; SHORT SURVEY;

EID: 0031047177     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.6.2.169     Document Type: Short Survey

References (18)